1. Home
  2. NBIX vs STLA Comparison

NBIX vs STLA Comparison

Compare NBIX & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

N/A

Current Price

$167.43

Market Cap

17.7B

Sector

Health Care

ML Signal

N/A

Logo Stellantis N.V.

STLA

Stellantis N.V.

N/A

Current Price

$3.84

Market Cap

20.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
NBIX
STLA
Founded
1992
2021
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
17.7B
20.2B
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
NBIX
STLA
Price
$167.43
$3.84
Analyst Decision
Strong Buy
Hold
Analyst Count
28
7
Target Price
★ $208.11
$6.39
AVG Volume (30 Days)
1.3M
★ 35.0M
Earning Date
11-02-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 41.95
N/A
EPS
★ 5.26
N/A
Revenue
★ $161,626,000.00
N/A
Revenue This Year
$39.52
$4.94
Revenue Next Year
$14.81
$2.21
P/E Ratio
$32.28
★ N/A
Revenue Growth
★ 977.51
N/A
52 Week Low
$122.14
$3.86
52 Week High
$186.12
$12.22

Technical Indicators

Market Signals
Indicator
NBIX
STLA
Relative Strength Index (RSI) 66.05 33.40
Support Level $152.67 N/A
Resistance Level $169.57 $4.83
Average True Range (ATR) 5.47 0.17
MACD 2.07 -0.05
Stochastic Oscillator 80.70 0.38

Price Performance

Historical Comparison
NBIX
STLA

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About STLA Stellantis N.V.

Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2025, it sold 5.6 million vehicles, 45%, 26%, and 18% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.

Share on Social Networks: